RVMD on Nasdaq
Revolution Medicines (United States)
In its 2026 annual report the company says: “We are a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. We possess sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites.”6 It was founded in 2014.1 It is headquartered in Redwood City.1 Its shares trade on Nasdaq under the symbol RVMD.1
Price unavailable
Last updated Oct 21, 2026.
Overview
2014Founded1
Compare with Caribou Biosciences, Inc., ELUTIA INC. or TScan Therapeutics, Inc., or pick any stock.
- TickerRVMD on Nasdaq1
- IndustryBiological Products, (No Diagnostic Substances)1
- HeadquartersRedwood City1
- Websitewww.revmed.com
- Incorporated inDE4
- Business address700 Saginaw Dr, Redwood City, Ca 940634
- Filer categoryLarge accelerated filer4
- Legal formCORPORATION3
- LEI549300JU3X0LBCQ658923
- StatusActive3
- LEI statusLapsed (not renewed)3
- Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States3
- Registered withDivision of Corporations, Department of State, 56116003
See how the biggest companies compare on our leaderboards
We are a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. We possess sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Guided by our understanding of genetic drivers and adaptive resistance mechanisms in cancer, we deploy precision medicine approaches to inform innovative monotherapy and combination regimens. Our research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors) that are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.6 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Financial statements
Every line of the income statement as filed: the last 4 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total revenue | $0 | $0 | $11.6M | |
| Research and development | $987.3M | $592.2M | $423.1M | |
| General and administrative | $195.0M | $97.3M | $75.6M | |
| Total operating expenses | $1.2B | $689.5M | $498.8M | |
| Loss from operations | -$1.2B | -$689.5M | -$487.2M | |
| Interest income | $90.7M | $86.9M | $47.5M | |
| Interest expense | -$24.2M | $0 | $0 | |
| Change in fair value of warrant liability and contingent earn-out shares | -$15.4M | $4.3M | $115.0K | |
| Other expense, net: | -$37.0K | -$2.5M | -$303.0K | |
| Total non-operating income, net | $51.1M | $88.7M | $47.3M | |
| Income (loss) before provision for income taxes | -$1.1B | -$600.8M | -$439.9M | |
| Benefit from income taxes | $0 | $753.0K | $3.5M | |
| Net loss | -$1.1B | -$600.1M | -$436.4M | |
| Net loss per share attributable to common stockholders, basic | -$5.95 | -$3.58 | -$3.86 | |
| Net loss per share attributable to common stockholders, diluted | -$5.95 | -$3.58 | -$3.86 | |
| Weighted-average common shares used to compute net loss per share, basic | 190.1M shares | 167.7M shares | 113.1M shares | |
| Weighted-average common shares used to compute net loss per share, diluted | 190.1M shares | 167.7M shares | 113.1M shares | |
| Unrealized gain on investments, net | $1.9M | $777.0K | $2.3M | $2.3M |
| Comprehensive loss | -$1.1B | -$599.3M | -$434.0M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $383.7M | $543.1M | $696.1M | |
| Marketable securities | $1.6B | $1.7B | ||
| Prepaid expenses and other current assets | $49.4M | $38.3M | ||
| Total current assets | $2.1B | $2.3B | ||
| Property and equipment, net | $33.2M | $24.3M | ||
| Operating lease right-of-use asset | $132.1M | $117.5M | ||
| Intangible assets, net | $55.8M | $56.7M | ||
| Goodwill | $14.6M | $14.6M | ||
| Restricted cash | $4.9M | $3.7M | ||
| Long-term deposits | $24.1M | $12.1M | ||
| Other noncurrent assets | $14.8M | $1.7M | ||
| Total assets | $2.4B | $2.6B | ||
| Accounts payable | $64.6M | $54.4M | ||
| Accrued expenses and other current liabilities | $209.3M | $96.6M | ||
| Operating lease liability, current | $16.5M | $12.9M | ||
| Total current liabilities | $290.4M | $163.9M | ||
| Deferred tax liability | $2.4M | $2.4M | ||
| Operating lease liability, noncurrent | $142.2M | $123.0M | ||
| Liability related to the sale of future royalties | $268.4M | $0 | ||
| Warrant liability | $18.5M | $3.2M | ||
| Other noncurrent liabilities | $1.2M | $670.0K | ||
| Total liabilities | $723.2M | $293.1M | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively; none issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $0 | $0 | ||
| Common stock, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2025 and December 31, 2024, respectively; 197,001,401 and 185,896,625 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $19.0K | $18.0K | ||
| Additional paid-in capital | $4.5B | $4.0B | ||
| Accumulated other comprehensive income | $3.2M | $1.3M | ||
| Accumulated deficit | -$2.9B | -$1.7B | ||
| Total stockholders' equity | $1.6B | $2.3B | $1.8B | $685.2M |
| Total liabilities and stockholders' equity | $2.4B | $2.6B | ||
| Preferred stock, par or stated value per share | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par or stated value per share | $0.00 | $0.00 | ||
| Common stock, shares authorized | 300.0M shares | 300.0M shares | ||
| Common stock, shares, issued | 197.0M shares | 185.9M shares | ||
| Common stock, shares, outstanding | 197.0M shares | 185.9M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $383.7M | $543.1M | $696.1M | |
| Marketable securities | $1.6B | $1.7B | ||
| Prepaid expenses and other current assets | $49.4M | $38.3M | ||
| Total current assets | $2.1B | $2.3B | ||
| Property and equipment, net | $33.2M | $24.3M | ||
| Operating lease right-of-use asset | $132.1M | $117.5M | ||
| Intangible assets, net | $55.8M | $56.7M | ||
| Goodwill | $14.6M | $14.6M | ||
| Restricted cash | $4.9M | $3.7M | ||
| Long-term deposits | $24.1M | $12.1M | ||
| Other noncurrent assets | $14.8M | $1.7M | ||
| Total assets | $2.4B | $2.6B | ||
| Accounts payable | $64.6M | $54.4M | ||
| Accrued expenses and other current liabilities | $209.3M | $96.6M | ||
| Operating lease liability, current | $16.5M | $12.9M | ||
| Total current liabilities | $290.4M | $163.9M | ||
| Deferred tax liability | $2.4M | $2.4M | ||
| Operating lease liability, noncurrent | $142.2M | $123.0M | ||
| Liability related to the sale of future royalties | $268.4M | $0 | ||
| Warrant liability | $18.5M | $3.2M | ||
| Other noncurrent liabilities | $1.2M | $670.0K | ||
| Total liabilities | $723.2M | $293.1M | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively; none issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $0 | $0 | ||
| Common stock, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2025 and December 31, 2024, respectively; 197,001,401 and 185,896,625 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $19.0K | $18.0K | ||
| Additional paid-in capital | $4.5B | $4.0B | ||
| Accumulated other comprehensive income | $3.2M | $1.3M | ||
| Accumulated deficit | -$2.9B | -$1.7B | ||
| Total stockholders' equity | $1.6B | $2.3B | $1.8B | $685.2M |
| Total liabilities and stockholders' equity | $2.4B | $2.6B | ||
| Preferred stock, par or stated value per share | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par or stated value per share | $0.00 | $0.00 | ||
| Common stock, shares authorized | 300.0M shares | 300.0M shares | ||
| Common stock, shares, issued | 197.0M shares | 185.9M shares | ||
| Common stock, shares, outstanding | 197.0M shares | 185.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$1.1B | -$600.1M | -$436.4M |
| Loss on disposal of fixed assets | $32.0K | $118.0K | $52.0K |
| Amortization of intangible assets | $870.0K | $1.1M | $1.1M |
| Stock-based compensation expense | $118.4M | $79.2M | $61.8M |
| Depreciation and amortization | $7.8M | $6.6M | $5.0M |
| Change in fair value of warrant liability and contingent earn-out shares | $15.4M | -$4.3M | $115.0K |
| Non-cash interest expense on liabilities related to sale of future royalties | $24.2M | $0 | $0 |
| Net amortization of premium or discount on marketable securities | -$27.8M | -$44.6M | -$22.2M |
| Amortization of operating lease right-of-use asset | $7.9M | $4.2M | $3.2M |
| Accounts receivable | $0 | $1.3M | $3.4M |
| Prepaid expenses and other current assets | -$9.7M | -$9.7M | -$2.6M |
| Accounts payable | $9.5M | -$6.5M | $32.5M |
| Accrued expenses and other current liabilities | $112.3M | $22.0M | $14.7M |
| Deferred revenue | $0 | $0 | -$4.5M |
| Operating lease liability | -$957.0K | -$245.0K | -$1.5M |
| Deferred tax liability | $0 | -$762.0K | -$3.9M |
| Long-term deposits | -$12.0M | -$7.6M | -$2.3M |
| Other noncurrent assets | -$12.9M | $1.7M | $870.0K |
| Other noncurrent liabilities | $537.0K | $212.0K | $157.0K |
| Net cash used in operating activities | -$897.7M | -$557.4M | -$350.6M |
| Purchases of marketable securities | -$1.8B | -$2.1B | -$1.1B |
| Maturities of marketable securities | $1.9B | $1.6B | $724.0M |
| Sales of marketable securities | $6.4M | $0 | $0 |
| Purchases of property and equipment | -$16.0M | -$10.3M | -$7.7M |
| Net cash provided by (used in) investing activities | $118.1M | -$554.4M | -$342.6M |
| Cash, cash equivalents and restricted cash acquired in connection with EQRx Acquisition, net of transaction costs | $0 | $0 | $840.8M |
| Proceeds from the sale of future royalties, net of issuance costs | $244.2M | $0 | $0 |
| Proceeds from issuance of common stock, net of issuance costs | $0 | $727.6M | $323.7M |
| Proceeds from issuance of pre-funded warrants, net of transaction costs | $0 | $95.4M | $0 |
| Proceeds from issuance of common stock from at-the-market offering, net of transaction costs | $347.9M | $118.7M | $62.1M |
| Proceeds from issuance of common stock pursuant to stock option exercises | $21.1M | $12.3M | $3.3M |
| Proceeds from issuance of common stock related to employee stock purchase plan | $8.0M | $5.0M | $3.3M |
| Tax payment for common stock withheld in satisfaction of withholding tax requirements | $0 | $0 | -$4.0M |
| Exercise of warrants | $4.0K | $0 | $0 |
| Payments of deferred offering costs | $220.0K | $284.0K | $0 |
| Net cash provided by financing activities | $621.5M | $959.4M | $1.2B |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -$158.2M | -$152.4M | $536.0M |
| Issuance of common stock for EQRx acquisition | $0 | $0 | $1.1B |
| Fair value of net assets acquired in connection with EQRx Acquisition | $0 | $0 | $291.5M |
| Purchases of property and equipment in accounts payable and accrued expenses and other current liabilities | $1.9M | $1.6M | $2.6M |
| Right-of-use assets obtained in exchange for operating lease liabilities | $22.5M | $44.6M | $25.3M |
No quarter-by-quarter statement was filed.
Compare Revolution Medicines (United States) with another company
Corporate structure
Revolution Medicines (United States) sits at the top of its group. 7 entities, 4 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Revolution Medicines (United States)
- BAKER BROS. ADVISORS LP Filed SCHEDULE 13G on Revolution Medicines (United States), latest Aug 14, 2026 (3 filings since Aug 14, 2025)
- FARALLON CAPITAL MANAGEMENT, L.L.C. Filed SCHEDULE 13G/A on Revolution Medicines (United States), latest Aug 13, 2026
- Janus Henderson Group Ltd. Filed SCHEDULE 13G on Revolution Medicines (United States), latest Aug 13, 2026 (6 filings since Feb 14, 2025)
- BlackRock Filed SCHEDULE 13G on Revolution Medicines (United States), latest Jul 29, 2026 (5 filings since Feb 3, 2022)
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on Revolution Medicines (United States), latest Mar 27, 2026 (4 filings since Feb 10, 2022)
- Wellington Management Company Filed SCHEDULE 13G/A on Revolution Medicines (United States), latest Feb 10, 2026 (8 filings since Feb 4, 2022)
- Farallon Capital Partners, L.P. Filed SCHEDULE 13G/A on Revolution Medicines (United States), latest Feb 9, 2026 (6 filings since Nov 9, 2023)
- FMR LLC Filed SCHEDULE 13G on Revolution Medicines (United States), latest Nov 5, 2025 (3 filings since Jan 10, 2022)
- BIOTECHNOLOGY VALUE FUND L P Filed SC 13G/A on Revolution Medicines (United States), latest Feb 14, 2024 (3 filings since Feb 14, 2022)
- EcoR1 Capital, LLC Filed SC 13G/A on Revolution Medicines (United States), latest Feb 14, 2024 (4 filings since Jun 27, 2022)
- BB Biotech Filed SC 13G/A on Revolution Medicines (United States), latest Feb 13, 2024 (3 filings since Sep 30, 2022)
- COLUMN GROUP III, LP Filed SC 13G/A on Revolution Medicines (United States), latest Feb 9, 2024 (3 filings since Feb 11, 2022)
- Revolution Medicines (United States) Redwood City, California, United States
- EQRx, LLC Subsidiary · Delaware, United States
- Revolution Medicines Japan KK Subsidiary · Japan
- Revolution Medicines Netherlands B.V. Subsidiary · Netherlands
- Revolution Medicines Switzerland GmbH Subsidiary · Germany
- Verum Norte Therapeutics, Inc. Subsidiary · Delaware, United States
- Warp Drive Bio, Inc. Subsidiary · Delaware, United States
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Revolution Medicines (United States) reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $61.7M7 Dec 31, 2025 | $46.1M7 Dec 31, 2024 | +33.8% |
| Accumulated depreciation | $28.5M7 Dec 31, 2025 | $21.8M7 Dec 31, 2024 | +30.7% |
| Property and equipment, net | $33.2M7 Dec 31, 2025 | $24.3M7 Dec 31, 2024 | +36.7% |
| Operating-lease assets (leased space) | $132.1M7 Dec 31, 2025 | $117.5M7 Dec 31, 2024 | +12.4% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $383.7M7 Dec 31, 2025 | $543.1M7 Dec 31, 2024 | −29.3% |
| Marketable securities, current | $1.6B7 Dec 31, 2025 | $1.7B7 Dec 31, 2024 | −6.0% |
| Debt securities available for sale | $2.0B7 Dec 31, 2025 | $2.3B7 Dec 31, 2024 | −11.5% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $14.6M7 Dec 31, 2025 | $14.6M7 Dec 31, 2024 | 0% |
| Intangible assets, net (excluding goodwill) | $55.8M7 Dec 31, 2025 | $56.7M7 Dec 31, 2024 | −1.5% |
| Indefinite-lived intangibles (excluding goodwill) | $55.8M7 Dec 31, 2025 | $55.8M7 Dec 31, 2024 | 0% |
| Finite-lived intangibles, gross | $7.5M7 Dec 31, 2025 | $7.5M7 Dec 31, 2024 | 0% |
| Accumulated amortization | $7.5M7 Dec 31, 2025 | $6.6M7 Dec 31, 2024 | +13.2% |
| Finite-lived intangibles, net | $07 Dec 31, 2025 | $870.0K7 Dec 31, 2024 | −100.0% |
Properties, in its own words
Our corporate headquarters is located in Redwood City, California, where we lease and occupy approximately 293,906 square feet of office and laboratory space. The term of our Redwood City lease expires in December 2035.
We believe our existing facilities are sufficient for our needs for the foreseeable future. To meet the future needs of our business, we may lease additional or alternate space, and we believe suitable additional or alternative space will be available in the future on commercially reasonable terms.
Item 2 of the 10-K filed Feb 25, 2026.6
Leadership
Who has led Revolution Medicines (United States), and when. Pick a name to see everywhere that person has worked.
Chief financial officer
Chief operating officer
201520202025
- Chief financial officerJack Anders Sep 2, 2022 to now15
- Chief operating officerMargaret A. Horn Nov 2, 2022 to now16
Board members and other officers (23)
- Chief Development OfficerAlan B. Sandler Mar 26, 2026 to now17
- OfficerAnthony Mancini Mar 26, 2026 to now18
- Chief Medical OfficerLin Wei Mar 29, 2024 to now19
- OfficerXiaolin Wang Mar 8, 2021 to now20
- OfficerJack Anders Feb 12, 2020 to Jun 22, 202221
- OfficerMargaret A. Horn Feb 12, 2020 to Mar 21, 202322
- OfficerMark A. Goldsmith Feb 12, 2020 to now23
- OfficerStephen Michael Kelsey Feb 12, 2020 to now24
- Board memberFrank Clyburn Aug 7, 2024 to now25
- Board memberSandra Horning Nov 14, 2023 to now26
- Board memberSushil Patel Jun 17, 2022 to now27
- Board memberLorence Kim Jul 13, 2022 to now28
- Board memberFlavia Borellini Jun 24, 2021 to now29
- Board memberAlexis Borisy Feb 12, 2020 to now30
- Board memberBarbara Weber Feb 12, 2020 to Oct 10, 202431
- Board memberElizabeth M. Anderson Feb 12, 2020 to now32
- Board memberLaurence Lasky Feb 12, 2020 to Feb 14, 202033
- Board memberMark A. Goldsmith Feb 12, 2020 to now23
- Board memberNeil Exter Feb 12, 2020 to Jun 17, 202234
- Board memberThilo Schroeder Feb 12, 2020 to Dec 9, 202435
- Board memberVincent A. Miller Feb 12, 2020 to Jun 24, 202136
- Board memberPeter Svennilson Jun 19, 2020 to Apr 28, 202137
- General counselJeff Cislini Mar 29, 2023 to now38
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- EQRx, LLC Delaware5
- Revolution Medicines Japan KK Japan5
- Revolution Medicines Netherlands B.V. Netherlands5
- Revolution Medicines Switzerland GmbH Germany5
- Verum Norte Therapeutics, Inc. Delaware5
- Warp Drive Bio, Inc. Delaware5
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Timeline
- Oct 13, 20268-K New debt or obligation; Other events39
- Sep 1, 20268-K Entered a material agreement; New debt or obligation40
- Aug 26, 20268-K Other events41
- Aug 5, 20268-K Results of operations42
- Jun 22, 20268-K Executive or director change; Shareholder vote43
- May 6, 20268-K Results of operations44
- Apr 17, 20268-K Entered a material agreement; New debt or obligation; Other events45
- Apr 16, 20268-K Other events46
- Apr 13, 20268-K Other events47
- Feb 25, 20268-K Results of operations48
- Nov 5, 20258-K Results of operations49
- Oct 17, 20258-K Other events50
- 2014Founded Founded1
Calendar
Coming up
- Nov 4, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($1.61) a share, on Nov 5, 2025.51
When it reported results
- Aug 5, 2026Reported quarterly or annual results42
- May 6, 2026Reported quarterly or annual results44
- Feb 25, 2026Reported quarterly or annual results48
- Nov 5, 2025Reported quarterly or annual results49
- Aug 6, 2025Reported quarterly or annual results52
- May 7, 2025Reported quarterly or annual results53
- Feb 26, 2025Reported quarterly or annual results54
- Nov 6, 2024Reported quarterly or annual results55
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
665 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 57 major events, 300 insider forms, 52 large holders, 236 other. The latest 20:
- Oct 13, 20268-K EDGAR
- Oct 1, 20264 EDGAR
- Sep 29, 20264 EDGAR
- Sep 29, 2026144 EDGAR
- Sep 28, 20264 EDGAR
- Sep 25, 2026144 EDGAR
- Sep 24, 2026144 EDGAR
- Sep 24, 20264 EDGAR
- Sep 22, 20264 EDGAR
- Sep 22, 2026144 EDGAR
- Sep 18, 20264 EDGAR
- Sep 18, 20264 EDGAR
- Sep 18, 2026144 EDGAR
- Sep 18, 20264 EDGAR
- Sep 18, 20264 EDGAR
- Sep 18, 20264 EDGAR
- Sep 18, 20264 EDGAR
- Sep 18, 20264 EDGAR
- Sep 15, 2026144 EDGAR
- Sep 15, 2026144 EDGAR
The 665 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
223 open-market trades by officers, directors and large owners since October 2021: 21 buys and 202 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 25, 2026 | Mancini AnthonySee Remarks | Sale | 3,121 | $200.54 | $625.9K | Form 4 |
| Sep 25, 2026 | Cislini JeffSVP & General Counsel | Sale | 765 | $207.32 | $158.6K | Form 4 |
| Sep 24, 2026 | Mancini AnthonySee Remarks | Sale | 587 | $200.00 | $117.4K | Form 4 |
| Sep 22, 2026 | ANDERSON ELIZABETH MDirector | Sale | 10,143 | $193.04 | $2.0M | Form 4 |
| Sep 18, 2026 | Mancini AnthonySee Remarks | Sale | 1,764 | $196.94 | $347.4K | Form 4 |
| Sep 16, 2026 | Mancini AnthonySee Remarks | Sale | 1,774 | $199.24 | $353.4K | Form 4 |
| Sep 16, 2026 | Cislini JeffSVP & General Counsel | Sale | 3,366 | $199.23 | $670.6K | Form 4 |
| Sep 16, 2026 | Sandler Alan B.Chief Development Officer | Sale | 341 | $199.24 | $67.9K | Form 4 |
| Sep 16, 2026 | Anders JackChief Financial Officer | Sale | 4,053 | $199.24 | $807.5K | Form 4 |
| Sep 16, 2026 | Kelsey Stephen MichaelSee Remarks | Sale | 5,569 | $199.23 | $1.1M | Form 4 |
| Sep 16, 2026 | Horn Margaret AChief Operating Officer | Sale | 4,967 | $199.23 | $989.6K | Form 4 |
| Sep 16, 2026 | GOLDSMITH MARK ASee Remarks | Sale | 13,988 | $199.23 | $2.8M | Form 4 |
| Sep 11, 2026 | Kelsey Stephen MichaelSee Remarks | Sale | 92,531 | $202.36 | $18.7M | Form 4 |
| Sep 10, 2026 | Mancini AnthonySee Remarks | Sale | 15,448 | $204.16 | $3.2M | Form 4 |
| Sep 8, 2026 | Kim Lorence H.Director | Sale | 17,090 | $209.82 | $3.6M | Form 4 |
| Aug 31, 2026 | Kim Lorence H.Director | Sale | 56,000 | $203.24 | $11.4M | Form 4 |
| Aug 21, 2026 | Cislini JeffSVP & General Counsel | Sale | 56,894 | $209.24 | $11.9M | Form 4 |
| Aug 21, 2026 | GOLDSMITH MARK ASee Remarks | Sale | 86,000 | $209.20 | $18.0M | Form 4 |
| Jun 29, 2026 | Patel SushilDirector | Sale | 5,580 | $187.99 | $1.0M | Form 4 |
| Jun 24, 2026 | Anders JackChief Financial Officer | Sale | 20,000 | $168.33 | $3.4M | Form 4 |
All 223 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- BAKER BROS. ADVISORS LPSCHEDULE 13G, 3 filings Aug 14, 2025 to Aug 14, 202656
- FARALLON CAPITAL MANAGEMENT, L.L.C.SCHEDULE 13G/A, 1 filing Aug 13, 202657
- Janus Henderson Group Ltd.SCHEDULE 13G, 6 filings Feb 14, 2025 to Aug 13, 202658
- BlackRockSCHEDULE 13G, 5 filings Feb 3, 2022 to Jul 29, 202659
- VANGUARD GROUP INCSCHEDULE 13G/A, 4 filings Feb 10, 2022 to Mar 27, 202660
- Wellington Management CompanySCHEDULE 13G/A, 8 filings Feb 4, 2022 to Feb 10, 202661
- Farallon Capital Partners, L.P.SCHEDULE 13G/A, 6 filings Nov 9, 2023 to Feb 9, 202662
- FMR LLCSCHEDULE 13G, 3 filings Jan 10, 2022 to Nov 5, 202563
- BIOTECHNOLOGY VALUE FUND L PSC 13G/A, 3 filings Feb 14, 2022 to Feb 14, 202464
- EcoR1 Capital, LLCSC 13G/A, 4 filings Jun 27, 2022 to Feb 14, 202465
- BB BiotechSC 13G/A, 3 filings Sep 30, 2022 to Feb 13, 202466
- COLUMN GROUP III, LPSC 13G/A, 3 filings Feb 11, 2022 to Feb 9, 202467
- Third Rock Ventures III, L.P.SC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202368
- Cormorant Asset Management, LPSC 13G/A, 1 filing Feb 14, 202269
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Mark A. GoldsmithM.D., Ph.D. | $812.5K | $14.7M70 | |
| 2025 | Stephen M. KelseyM.D., FRCP, FRCPath | $625.8K | $6.0M70 | |
| 2025 | Margaret HornJ.D. | 63 | $582.7K | $4.8M70 |
| 2025 | Jeffrey Cislini | 51 | $523.8K | $3.7M70 |
| 2025 | Jack Anders | 49 | $523.3K | $3.6M70 |
| 2024 | President and Chief Executive Officer | $689.2K | $10.1M70 | |
| 2024 | PresidentResearch and Development | $573.3K | $5.9M70 | |
| 2024 | Chief Operating Officer | $540.8K | $4.9M70 | |
| 2024 | Chief Financial Officer | $473.3K | $3.3M70 | |
| 2024 | General Counsel and Secretary | $477.2K | $2.7M70 | |
| 2023 | President and Chief Executive Officer | $631.1K | $10.4M70 | |
| 2023 | PresidentResearch and Development | $512.6K | $4.4M70 | |
| 2023 | Chief Operating Officer | $512.6K | $4.4M70 | |
| 2023 | Chief Financial Officer | $438.4K | $3.0M70 | |
| 2023 | General Counsel and Secretary | $405.0K | $2.6M70 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 13,695,790 | $2.6B | 0.0% | +2,483,084 |
| Farallon Capital Management, L.l.c. | 13,550,796 | $2.5B | 15.0% | −54,000 |
| Fmr LLC | 12,200,422 | $2.3B | 0.1% | +3,736,108 |
| Baker Bros. Advisors LP | 11,443,357 | $2.1B | 10.8% | +1,888,000 |
| Darwin Global Management, Ltd. | 10,629,822 | $2.0B | 54.5% | +8,418,804 |
| Jupiter Topco LLC | 10,736,145 | $2.0B | 0.8% | New |
| Vanguard Capital Management LLC | 9,088,661 | $1.7B | 0.0% | +726,377 |
| Vanguard Portfolio Management LLC | 8,294,855 | $1.6B | 0.1% | +792,232 |
| Nextech Invest Ltd. | 7,601,087 | $1.4B | 67.6% | No change |
| Paradigm Biocapital Advisors LP | 6,361,323 | $1.2B | 22.3% | −294,380 |
| UBS Group AG | 5,448,364 | $1.0B | 0.2% | +1,061,573 |
| State Street Corp | 4,897,051 | $917.1M | 0.0% | +494,389 |
| Capital World Investors | 4,008,244 | $750.7M | 0.1% | New |
| Geode Capital Management, LLC | 3,942,676 | $736.8M | 0.0% | +604,534 |
| Wellington Management Group Llp | 3,843,415 | $719.8M | 0.1% | −2,184,404 |
| Jpmorgan Chase & Co | 3,298,066 | $636.9M | 0.0% | +2,996,673 |
| Bvf Inc/il | 2,965,160 | $555.3M | 14.2% | +108,378 |
| Alphabet Inc. | 2,946,619 | $551.8M | 0.6% | −345,906 |
| Casdin Capital, LLC | 2,577,333 | $482.7M | 24.2% | No change |
| Deerfield Management Company, L.P. | 2,392,000 | $448.0M | 5.6% | +95,000 |
| Avoro Capital Advisors LLC | 2,297,000 | $430.2M | 3.9% | −47,444 |
| Norges Bank | 2,157,479 | $404.1M | 0.0% | New |
| Goldman Sachs Group Inc | 2,133,101 | $399.5M | 0.0% | −52,399 |
| Nearwater Capital Markets, Ltd | 2,097,000 | $392.7M | 6.8% | +1,419,000 |
| Massachusetts Financial Services Co /ma/ | 2,012,317 | $376.8M | 0.1% | New |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Revolution Medicines (United States) is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARRevolution Medicines, Inc.2
- CIK0001628171
- Employer ID (EIN)47-20291806
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company6
- Incorporated inDelaware6
- Fiscal year endsDecember 312
- Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)2
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
- Business address700 Saginaw Dr, Redwood City, CA 940632
- Phone650-481-68012
- Shares outstanding214,336,418 as of Jul 31, 202613
- Public float$6.7B as of Jun 30, 20256
- AuditorPricewaterhouseCoopers LLP, San Jose, California PCAOB ID 238; it also attests to the company’s internal control over financial reporting6
- On EDGAR sinceDec 21, 20162
- Filings858 in all: 4 (372), 144 (176), 8-K (71), SC 13G/A (30), 3 (26), 10-Q (20), SC 13G (17), 424B5 (13)2
All 41 form types
SCHEDULE 13G/A (13), CORRESP (11), 4/A (9), 425 (9), UPLOAD (9), DEFA14A (8), 10-K (7), S-8 (7), SCHEDULE 13G (7), DEF 14A (6), ARS (4), EFFECT (4), 424B4 (3), D (3), DRS (3), S-1 (3), S-1/A (3), S-3ASR (3), 8-A12B (2), CERT (2), DRS/A (2), DRSLTR (2), FWP (2), SEC STAFF LETTER (2), 144/A (1), 3/A (1), 305B2 (1), 424B3 (1), 8-K/A (1), DEFM14A (1), S-1MEF (1), S-4 (1), S-4/A (1)
- Latest filingsAnnual report (10-K) Feb 25, 2026
Quarterly report (10-Q) Aug 5, 2026
Proxy statement (DEF 14A) Apr 27, 2026
Latest 8-K (8-K) Oct 13, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock $0.0001 Par Value per Share | RVMD | The Nasdaq Stock Market LLC |
| Warrants to purchase 0.1112 shares of common stock expiring 2026 | RVMDW | The Nasdaq Stock Market LLC |
From the cover page of the 10-K filed Feb 25, 2026 (Section 12(b) of the Exchange Act).6
Risk factors and legal proceedings
The risks Revolution Medicines (United States) names in Item 1A of its 10-K filed Feb 25, 2026: 74 risks under these headings, as written.6
- Risks related to our limited operating history, financial position and need for additional capital
- We are a clinical-stage precision oncology company with a limited operating history and no products approved for commercial sale. We have incurred significant losses since our inception. We expect to incur losses for at least the next several years and may never achieve or maintain profitability, which, together with our limited operating history, makes it difficult to assess our future viability.
- We have never generated revenue from product sales and may never be profitable.
- We will require substantial additional financing to achieve our goals, which may not be available on acceptable terms, or at all. A failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts.
- The Royalty Pharma Agreements place restrictions on our operating and financial flexibility. If we fail to comply with certain covenants in the Royalty Pharma Agreements, our financial condition and results of operations may be harmed.
- Our operating results may fluctuate significantly, which will make our future results difficult to predict and could cause our results to fall below expectations.
- Risks related to product development and regulatory process
- Our business is dependent on the successful development of our current and future product candidates. If we, alone or in collaboration, are unable to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any of our product candidates, or we experience significant delays in doing so, our business will be materially harmed.
- Preclinical development is uncertain. Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize our product candidates on a timely basis or at all, which would have an adverse effect on our business.
- The results of preclinical studies and early-stage clinical trials may not be predictive of future results.
- If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
- We and our collaborators are currently developing, and may in the future develop, our product candidates in combination with other therapies, which exposes us to additional risks.
The other 63 risks
- We face significant competition, and if our competitors develop and market products that are more effective, safer or less expensive than our product candidates, our commercial opportunities will be negatively impacted.
- The regulatory approval processes of the FDA, the EMA and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable, and if we or our potential future collaboration partners are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.
- Clinical product development involves a lengthy and expensive process, with uncertain outcomes. We or our potential future collaboration partners may experience delays in completing, or ultimately be unable to complete, the development and commercialization of our current and future product candidates.
- Interim, “topline” and preliminary data from our clinical trials may differ materially from the final data.
- Our current or future product candidates may cause undesirable side effects or have other properties when used alone or in combination with other approved products or investigational new drugs that could delay or halt their clinical development, prevent their marketing approval, limit their commercial potential or result in significant negative consequences.
- Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us or any of our existing or potential future collaboration partners from obtaining approvals for the commercialization of any of our product candidates.
- Obtaining and maintaining marketing approval of our current and future product candidates in one jurisdiction does not mean that we or our potential future collaboration partners will be successful in obtaining marketing approval of our current and future product candidates in other jurisdictions.
- Adverse events in the field of oncology or the biopharmaceutical industry could damage public perception of our current or future product candidates and negatively affect our business.
- Even if we or our potential future collaboration partners receive marketing approval of a product candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products, if approved.
- Even if a current or future product candidate receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.
- Even if we are able to commercialize any product candidates, such products may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies.
- We may fail to select or capitalize on the most scientifically, clinically and commercially promising or profitable drug candidates including mutant RAS(ON) targets.
- We may not be successful in our efforts to identify or discover other product candidates and may fail to capitalize on programs, product candidates or indications or lines of therapy for which there is a greater likelihood of success or that may present a greater commercial opportunity.
- We may need to use existing commercial diagnostic tests or develop, or enter into a collaboration or partnership to develop, novel complementary diagnostics and/or novel companion diagnostics for some of our current or future product candidates. If we or our partners are unable to successfully develop these companion diagnostics or complementary diagnostics, or experience significant delays in doing so, we may not realize the full commercial potential of our future product candidates.
- We may seek and fail to obtain fast track or breakthrough therapy designations for our current or future product candidates. Even if we are successful, these programs may not lead to a faster development or regulatory review process, and they do not guarantee we will receive approval for any product candidate.
- We may seek orphan drug designation for our product candidates, and we may be unsuccessful or may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.
- We have received a Commissioner’s National Priority Voucher (CNPV) from FDA for daraxonrasib, but we may not realize any benefit from our participation in the FDA’s CNPV Pilot Program, and any changes to or termination of the CNPV Pilot Program could delay or adversely affect development and review of our product candidates.
- If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of any approved products.
- Healthcare legislative reform measures may significantly impact our business and results of operations.
- Disruptions at the FDA and other government agencies caused by funding shortages, staffing limitations or global health concerns could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
- We are subject to stringent privacy laws, information security policies and contractual obligations governing the use, processing and transfer of personal information.
- Our business may be affected by the evolving regulatory framework for artificial intelligence, machine learning, and automated decision-making technologies, as well as the operational, cybersecurity and confidentiality risks associated with our use of such technologies.
- Our business and operations, or those of our CROs or other third parties, may suffer in the event of information technology system failures, cyberattacks or deficiencies in our cybersecurity, which could materially affect our business, financial condition and results of operations.
- Risks related to reliance on third parties
- We may depend on collaborations with other third parties for the development and commercialization of our product candidates in the future. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.
- We may seek to establish additional collaborations, and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans.
- If conflicts arise between us and our collaborators or strategic partners, these parties may act in a manner adverse to us and could limit our ability to implement our strategies.
- We rely on third parties to conduct the clinical trials for our product candidates. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain marketing approval for or commercialize our product candidates.
- We rely on third parties to manufacture preclinical and clinical drug supplies, and we intend to rely on third parties to produce commercial supplies of any approved product, which increases the risk that we will not have sufficient quantities of these product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.
- Our future relationships with customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, transparency, and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings.
- Risks related to intellectual property
- If we and our collaborators are unable to obtain and maintain sufficient patent and other intellectual property protection for our product candidates and technology, our competitors could develop and commercialize products and technology similar or identical to ours, and we may not be able to compete effectively in our market or successfully commercialize any of our current or future product candidates.
- We have entered into license agreements with third parties. If we or a third party fail to comply with the obligations in the agreements under which we license intellectual property rights to or from third parties, or these agreements are terminated, or we otherwise experience disruptions to business relationships with our licensors or licensees, our competitive position, business, financial condition, results of operations and prospects could be harmed.
- If we are unable to obtain licenses from third parties on commercially reasonable terms or at all, our business could be harmed.
- We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might subject us to infringement claims or adversely affect our ability to develop and market our product candidates.
- Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.
- We may not be able to protect our intellectual property rights throughout the world.
- Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.
- Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated if we fail to comply with these requirements.
- We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful, and issued patents covering our technology and product candidates could be found invalid or unenforceable if challenged.
- Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could negatively impact the success of our business.
- We may be subject to claims by third parties asserting that we or our employees have infringed upon, misappropriated or otherwise violated their intellectual property rights, or claiming ownership of what we regard as our own intellectual property.
- We may be subject to claims challenging the inventorship of our patents and other intellectual property.
- If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
- If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest, and our business may be adversely affected.
- Intellectual property rights do not necessarily address all potential threats.
- Risks related to employee matters and managing our growth
- We are highly dependent on our key personnel, and if we are not successful in attracting, motivating and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.
- We will need to increase the size of our organization, and we may experience difficulties in managing this growth.
- We are currently building out our commercial organization. If we are unable to establish sufficient sales and marketing capabilities on our own or through third parties, we may not be able to market and sell any products effectively, if approved, or generate product revenue.
- We have in the past engaged and may in the future engage in strategic transactions; these transactions could affect our liquidity, dilute our existing stockholders, increase our expenses and present significant challenges in focus and energy to our management or prove not to be successful.
- If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could negatively impact our business.
- We or the third parties upon whom we depend are subject to risk from earthquakes, outbreak of disease, other natural disasters and catastrophic events and may be subject to disruption as a result of war, terrorism, political unrest and other causes.
- Our employees, independent contractors, vendors, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.
- Risks related to our common stock and warrants
- The price of our common stock is volatile and fluctuates substantially, which could result in substantial losses for investors.
- An active and liquid market for our common stock may not be sustained.
- We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.
- Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.
- There is no guarantee that the warrants will ever be in the money, and they may expire worthless.
- We may amend the terms of the warrants in a manner that may be adverse to holders with the approval by the holders of at least 50% of the then-outstanding warrants. As a result, the exercise price of a holder’s warrants could be increased, the exercise period could be shortened and the number of shares of our common stock purchasable upon exercise of a warrant could be decreased, all without the approval of that warrant holder.
- We may redeem unexpired warrants prior to their exercise at a time that is disadvantageous to warrant holders, thereby making their warrants worthless.
- Our ability to utilize our net operating loss carryforwards and certain other tax attributes has been limited by “ownership changes” and may be further limited.
- Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.
- Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.
- Our amended and restated certificate of incorporation and amended and restated bylaws provide for an exclusive forum in the Court of Chancery of the State of Delaware for certain disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
- General risk factors
- Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies.
Legal proceedings
From time to time, we are and may become involved in litigation or other legal proceedings arising from the normal course of business activities. Defending such proceedings is costly and can impose a significant burden on management and employees. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.
On December 9, 2024, Nemeth v. Casdin, et al., Case No. 2024-1268-KSJM (Del. Ch.), was filed in the Court of Chancery of the State of Delaware (the Complaint) arising from CM Life Sciences III., Inc.’s (CMLS III) December 17, 2021 merger with EQRx, Inc. (Legacy EQRx) (the Merger). The Complaint was filed by former stockholders of CMLS III and brings claims for breach of fiduciary duty and unjust enrichment against members of CMLS III’s board of directors, CMLS III’s officers, and CMLS III’s sponsor in connection with the Merger. The Complaint also brings claims for aiding and abetting breaches of fiduciary duties against certain investment firms involved with the merger process, the Company, solely as successor-in-interest to EQRx, and Legacy EQRx’s former Executive Chairman and CEO, Alexis Borisy, who is also on the Company’s board of directors. Defendants moved to dismiss the Complaint in February 2025. The parties reached an agreement to resolve the matter, which was filed with the court on January 6, 2026, and remains subject to court approval. We have recorded an accrual of $5.0 million in accrued and other current liabilities as of December 31, 2025, based on its expected contribution under the agreement and anticipated insurance recoveries.
The opening of Item 3, Legal Proceedings.6
Links
- Websitewww.revmed.com1
- WikidataQ107518109
- SEC EDGARCIK 1628171
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15SEC EDGARJack Anders, Chief financial officer
- 16
- 17
- 18SEC EDGARAnthony Mancini, Officer
- 19SEC EDGARLin Wei, Chief Medical Officer
- 20SEC EDGARXiaolin Wang, Officer
- 21SEC EDGARJack Anders, Officer
- 22SEC EDGARMargaret A. Horn, Officer
- 23SEC EDGARMark A. Goldsmith, Officer
- 24SEC EDGARStephen Michael Kelsey, Officer
- 25SEC EDGARFrank Clyburn, Board member
- 26SEC EDGARSandra Horning, Board member
- 27SEC EDGARSushil Patel, Board member
- 28SEC EDGARLorence Kim, Board member
- 29SEC EDGARFlavia Borellini, Board member
- 30SEC EDGARAlexis Borisy, Board member
- 31SEC EDGARBarbara Weber, Board member
- 32SEC EDGARElizabeth M. Anderson, Board member
- 33SEC EDGARLaurence Lasky, Board member
- 34SEC EDGARNeil Exter, Board member
- 35SEC EDGARThilo Schroeder, Board member
- 36SEC EDGARVincent A. Miller, Board member
- 37SEC EDGARPeter Svennilson, Board member
- 38SEC EDGARJeff Cislini, General counsel
- 39SEC EDGARNew debt or obligation; Other events
- 40
- 41SEC EDGAROther events
- 42SEC EDGARResults of operations
- 43
- 44SEC EDGARResults of operations
- 45
- 46SEC EDGAROther events
- 47SEC EDGAROther events
- 48SEC EDGARResults of operations
- 49SEC EDGARResults of operations
- 50SEC EDGAROther events
- 51NasdaqNasdaq calendar
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70